MUSTANG BIO INC (MBIO) Fundamental Analysis & Valuation

NASDAQ:MBIO • US62818Q3020

Current stock price

0.728 USD
+0 (+0.4%)
Last:

This MBIO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. MBIO Profitability Analysis

1.1 Basic Checks

  • In the past year MBIO has reported negative net income.
  • In the past year MBIO has reported a negative cash flow from operations.
  • In the past 5 years MBIO always reported negative net income.
  • MBIO had a negative operating cash flow in each of the past 5 years.
MBIO Yearly Net Income VS EBIT VS OCF VS FCFMBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -10.92%, MBIO belongs to the top of the industry, outperforming 82.20% of the companies in the same industry.
  • MBIO's Return On Equity of -20.16% is amongst the best of the industry. MBIO outperforms 82.01% of its industry peers.
Industry RankSector Rank
ROA -10.92%
ROE -20.16%
ROIC N/A
ROA(3y)-157%
ROA(5y)-121.58%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MBIO Yearly ROA, ROE, ROICMBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K -40K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MBIO Yearly Profit, Operating, Gross MarginsMBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. MBIO Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for MBIO has been increased compared to 1 year ago.
  • MBIO has more shares outstanding than it did 5 years ago.
  • MBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MBIO Yearly Shares OutstandingMBIO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
MBIO Yearly Total Debt VS Total AssetsMBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -31.59, we must say that MBIO is in the distress zone and has some risk of bankruptcy.
  • MBIO's Altman-Z score of -31.59 is on the low side compared to the rest of the industry. MBIO is outperformed by 88.39% of its industry peers.
  • MBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -31.59
ROIC/WACCN/A
WACCN/A
MBIO Yearly LT Debt VS Equity VS FCFMBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 2.22 indicates that MBIO has no problem at all paying its short term obligations.
  • With a Current ratio value of 2.22, MBIO is not doing good in the industry: 73.31% of the companies in the same industry are doing better.
  • MBIO has a Quick Ratio of 2.22. This indicates that MBIO is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 2.22, MBIO is not doing good in the industry: 71.37% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.22
Quick Ratio 2.22
MBIO Yearly Current Assets VS Current LiabilitesMBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MBIO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 99.08% over the past year.
EPS 1Y (TTM)99.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 17.03% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y88.69%
EPS Next 2Y39.32%
EPS Next 3Y26.7%
EPS Next 5Y17.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MBIO Yearly Revenue VS EstimatesMBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
MBIO Yearly EPS VS EstimatesMBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -200 -400 -600 -800

More info and screens

Find the best growth stocksShow best growing peers

1

4. MBIO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MBIO. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MBIO Price Earnings VS Forward Price EarningsMBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MBIO Per share dataMBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as MBIO's earnings are expected to grow with 26.70% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.32%
EPS Next 3Y26.7%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MBIO Dividend Analysis

5.1 Amount

  • No dividends for MBIO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MBIO Fundamentals: All Metrics, Ratios and Statistics

MUSTANG BIO INC

NASDAQ:MBIO (3/31/2026, 8:00:00 PM)

0.728

+0 (+0.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26
Earnings (Next)05-12
Inst Owners8.56%
Inst Owner Change96.7%
Ins Owners0.05%
Ins Owner Change34.05%
Market Cap5.31M
Revenue(TTM)N/A
Net Income(TTM)-1.92M
Analysts82.86
Price TargetN/A
Short Float %1.38%
Short Ratio0.43
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-0.4
EYN/A
EPS(NY)-2.02
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS0
BVpS1.31
TBVpS1.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -10.92%
ROE -20.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-157%
ROA(5y)-121.58%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.22
Quick Ratio 2.22
Altman-Z -31.59
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.17%
EPS Next Y88.69%
EPS Next 2Y39.32%
EPS Next 3Y26.7%
EPS Next 5Y17.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y60.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y53.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.87%
OCF growth 3YN/A
OCF growth 5YN/A

MUSTANG BIO INC / MBIO Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MUSTANG BIO INC (MBIO) stock?

ChartMill assigns a fundamental rating of 2 / 10 to MBIO.


What is the valuation status of MUSTANG BIO INC (MBIO) stock?

ChartMill assigns a valuation rating of 1 / 10 to MUSTANG BIO INC (MBIO). This can be considered as Overvalued.


What is the profitability of MBIO stock?

MUSTANG BIO INC (MBIO) has a profitability rating of 2 / 10.